EGFR and neoplasm: Since combination treatment can promote the efficacy of immunotherapy by increasing both tumor mutation burden (TMB) and tumor antigen exposure,18, 19 combination therapy has become one of the major research trends for EGFR‐TKI‐resistant patients.20, 21, 22